I don't think anybody was expecting strong statistical significance (p =0.010 for the large 6 months since diagnosis popuation ... p=0.023 for non-current smokers ... p=0.017 for patients with no liver or bone mets).
Of course the p would really become microscopic if 2 or more of these restictions were combined.
It looks like there's about 97 different ways Synta can design the Phase 3 trial so that it will succeed. Tough problem!
I sold about 20% of my SNTA before the initial interim data release when it was over $8, then bought back all those shares back around $6.50. I have no plans to lighten up again unless we get a major spike tomorrow. If SNTA drops or drifts lower through the end of the year, I will add to my position.
SNTA does not have the greatest following but the data is outstanding. It will go up as data good and will lead to partnership. lot of resistance but if breaks could be all time high . who cares SNTA great long term investment.